[March 23, 2005] Dyax to Present at Lehman Brothers Annual Global Healthcare Conference Tweet CAMBRIDGE, Mass. --(Business Wire)-- March 23, 2005 -- Dyax Corp. (Nasdaq:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Henry E. Blair, Chairman, President and Chief Executive Officer of Dyax, will present at Lehman Brothers' Eighth Annual Global Healthcare Conference, being held March 30-April 1, 2005 at the Loews Miami Beach Hotel. Mr. Blair will present a corporate progress report, including an update on the Company's clinical development programs. The Dyax presentation is scheduled for Wednesday, March 30 at 3:15 pm (ET). The Dyax presentation will be webcast live and may be accessed by visiting the Investor Relations section of the company website at www.dyax.com. The 25-minute presentation includes a brief question and answer period and will be available on the Dyax website for a limited period of time following the conference. About Dyax Dyax Corp. is focused on advancing novel biotherapeutics for unmet medical needs, with and emphasis on cancer and inflammatory indications. Dyax combines its proprietary drug discovery technology with its clinical development capabilities to advance antibody, small protein and peptide compounds. DX-88 and DX-890 are recombinant small proteins discovered at Dyax that are currently in clinical development for their therapeutic potential in three separate indications. In partnership with Genzyme Corporation, Dyax has successfully completed two Phase II trials of DX-88 for the treatment of hereditary angioedema (HAE). A third Phase II trial is ongoing, and an additional trial is planned. Independently, Dyax has successfully completed a Phase I/II trial of DX-88 for the prevention of blood loss during on-pump open heart surgery (CABG procedures) and is in partnering discussion with respect to Phase II trials. Dyax's partner for DX-890, Debiopharm SA, has completed Phase IIa trials and initiated a Phase IIb trial of DX-890 for the treatment of cystic fibrosis (CF). Both compounds have orphan drug designation in the US and EU, and DX-88 also has Fast Track designation in the US for the treatment of HAE. Both DX-88 and DX-890 were identified using Dyax's patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages its technology broadly with over 75 revenue-generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Dyax is headquartered in Cambridge, Massachusetts, and has antibody discovery facilities in Liege, Belgium. For online information about Dyax Corp., please visit www.dyax.com. [ Back To TMCnet.com's Homepage ]